Swiss pharma giant Novartis mulls sale of its Indian operations
KEYSTONE
Novartis has announced that it is considering various strategic options regarding the future of its Indian subsidiary Novartis India Limited, which is listed on the Bombay stock exchange. These include the possibility of selling its stake in the company.
This content was published on
2 minutes
“This strategic review will include a valuation of the 70.68% stake in the company,” Novartis India Limited said in a statement. This does not include the subsidiary Novartis Healthcare Private Limited, a separate entity wholly owned by the Basel-based group.
The latter includes the Novartis Corporate Center in Hyderabad, the commercial arm of Novartis in India, as well as research and development teams currently conducting clinical trials at more than 300 sites in the country. Novartis says it remains committed to its operations in India, where it employs more than 8100 associates.
There is no guarantee that this strategic review will be concluded in 2024 or that it will result in a transaction, it says.
At the end of December, Novartis India Limited recorded sales of 2.54 billion rupees (CHF26.9 million) in the first nine months of its offbeat financial year. According to Fierce Pharma, a specialised industry website, the Novartis India Limited subsidiary is involved in the distribution of medicines that are no longer protected by patent, particularly in the treatment of bone, pain, immunology and neuroscience.
In 2022, the distribution rights for some of this entity’s medicines were transferred to the Indian company Dr Reddy’s Laboratories, which, according to various Indian media, is among the potential buyers.
Translated from French by DeepL/ac
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
Compensation for Syrian after pregnant wife denied help on Swiss train
This content was published on
Switzerland’s Federal Court has partially upheld the appeal of a Syrian family being deported from Switzerland to Italy in 2014. The man now also receives compensation.
Swiss-EU negotiations: Cassis to meet Sefcovic in Bern
This content was published on
Swiss Foreign Minister Ignazio Cassis will meet the Vice-President of the EU Commission, Maros Sefcovic, in Bern on Wednesday.
Heavy snowfall in Switzerland causes traffic chaos and accidents
This content was published on
The heavy snowfall late on Thursday and during the night into Friday led to traffic chaos and many accidents in many regions of Switzerland.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.